Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
1. A heterologous chimeric protein comprising:
(a) a first domain comprising a portion of PD-1 that is at least 95% identical to SEQ ID NO: 32 and is capable of binding a PD-1 ligand,
(b) a second domain comprising a portion of OX-40 ligand (OX40L) that is at least 95% identical to SEQ ID NO: 56 and is capable of binding an OX-40L receptor, and
(c) a linker linking the first domain and the second domain and comprising a hinge-CH2-CH3 Fc domain.
2. The heterologous chimeric protein of claim 1 , wherein the heterologous chimeric protein is capable of inhibiting an immunosuppressive signal.
3. The heterologous chimeric protein of claim 1 , wherein the heterologous chimeric protein is capable of:
(a) reducing or eliminating an immune inhibitory signal when the portion of PD-1 is bound to its ligand and/or
(b) increasing or activating an immune stimulatory signal when the portion of OX40L is bound to its receptor.
4. The heterologous chimeric protein of claim 1 , wherein the PD-1 ligand is PD-L1 or PD-L2.
5. The heterologous chimeric protein of claim 1 , wherein the OX-40L receptor is OX40.
6. The heterologous chimeric protein of claim 1 , wherein the heterologous chimeric protein is capable of simultaneously binding the PD-1 ligand and the OX-40L receptor, wherein the PD-1 ligand is PD-L1 or PD-L2 and the OX-40L receptor is OX40.
7. The heterologous chimeric protein of claim 1 , wherein the heterologous chimeric protein is capable of increasing or preventing a decrease in a sub-population of CD4+ and/or CD8+ T cells.
8. The heterologous chimeric protein of claim 1 , wherein the heterologous chimeric protein is capable of enhancing tumor killing activity by T cells.
9. The heterologous chimeric protein of claim 1 , wherein the heterologous chimeric protein is capable of providing a sustained immunomodulatory effect.
10. The heterologous chimeric protein of claim 1 , wherein the hinge-CH2-CH3 Fc domain is derived from IgG4.
11. The heterologous chimeric protein of claim 10 , wherein the IgG4 is a human IgG4.
12. The heterologous chimeric protein of claim 1 , wherein the chimeric protein is expressed by a mammalian host cell as a secretable and functional single polypeptide chain.
13. The heterologous chimeric protein of claim 1 , wherein the portion of PD-1 is at least 97% identical to the amino acid sequence of SEQ ID NO: 32.
14. The heterologous chimeric protein of claim 1 , wherein the portion of OX40L is at least 97% identical to the amino acid sequence of SEQ ID NO: 56.
15. The heterologous chimeric protein of claim 13 , wherein the portion of OX40L is at least 97% identical to the amino acid sequence of SEQ ID NO: 56.
16. The heterologous chimeric protein of claim 1 , wherein the linker comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 71 or SEQ ID NO: 72.
17. The heterologous chimeric protein of claim 15 , wherein the linker comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 71 or SEQ ID NO: 72.
18. The heterologous chimeric protein of claim 17 , wherein the linker comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 71 or SEQ ID NO: 72.
19. An expression vector, comprising a nucleic acid encoding the heterologous chimeric protein of claim 1 .
20. A host cell, comprising the expression vector of claim 19 .
21. A pharmaceutical composition, comprising a therapeutically effective amount of the heterologous chimeric protein of claim 1 .
22. A method for treating cancer comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising:
(a) a first domain comprising a portion of PD-1 that is at least 95% identical to SEQ ID NO: 32 and is capable of binding a PD-1 ligand,
(b) a second domain comprising a portion of OX-40 ligand (OX40L) that is at least 95% identical to SEQ ID NO: 56 and is capable of binding an OX-40L receptor, and
(c) a linker linking the first domain and the second domain.
23. The method of claim 22 , wherein the subject's T cells are activated when bound by the second domain of the heterologous chimeric protein and:
(a) one or more tumor cells are prevented from transmitting an immunosuppressive signal when bound by the first domain of the heterologous chimeric protein,
(b) a quantifiable cytokine response in the peripheral blood of the subject is achieved, and/or
(c) tumor growth is reduced in the subject in need thereof as compared to a subject treated with OX40 agonist antibodies and/or PD-L1 blocking antibodies.
24. A recombinant fusion protein comprising:
(a) a first domain comprising a portion of PD-1 that is at least 95% identical to the amino acid sequence of SEQ ID NO: 32 and is capable of binding a PD-1 ligand,
(b) a second domain comprising a portion of OX-40 ligand (OX40L) that is at least 95% identical to the amino acid sequence of SEQ ID NO: 56 and is capable of binding an OX-40L receptor, and
(c) a linker comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 72 and links the first domain and the second domain.
25. A heterologous chimeric protein comprising:
(a) a first domain comprising the amino acid sequence of SEQ ID NO: 32,
(b) a second domain comprising the amino acid sequence of SEQ ID NO: 56, and
(c) a linker linking the first domain and the second domain and comprising the amino acid sequence of SEQ ID NO: 72.